Table of Contents
- Trial overview
- Who is being studied
- What the trials measure
- How the trials are designed
- What these studies may mean for patients
Trial overview
Two authorized Phase 3 trials are studying Sacubitril Valsartan in people with heart failure.[1][2] One trial is focused on a possible sex gap in heart failure treatment, meaning differences between women and men in how guideline-directed medical therapy is prescribed and used.[1] The other trial studies whether blood drug levels are more useful than the dose itself for understanding heart failure control.[2]
Who is being studied
The first study includes patients with heart failure and focuses especially on women in a prospective, pragmatic, multicentre trial.[1] The second study includes patients with chronic heart failure with reduced ejection fraction, which means long-term heart failure where the heart pumps out less blood than normal.[2] Together, these studies look at adults with heart failure in different clinical settings.[1][2]
What the trials measure
The first trial measures all-cause mortality, heart failure readmission, and worsening heart failure within 1 year.[1] It also studies quality of life, adherence to treatment, and side effects.[1] The second trial measures whether serum concentrations of the listed medicines, including Sacubitril Valsartan, are linked to clinical indicators of heart failure.[2]
How the trials are designed
The first study has both a retrospective part and a prospective part.[1] The retrospective part reviews national registry and database data to describe current prescribing patterns and inequality related to sex.[1] The prospective part compares up-titration of guideline-directed medical therapy, using the STRONG-HF titration programme, with usual care.[1]
The second study is an interventional Phase 3 trial that compares several heart failure medicines, including beta-blockers, spironolactone, and Sacubitril Valsartan, by looking at their serum concentrations and clinical effects.[2] Its goal is to see whether drug levels in the blood are more important than the prescribed dose for compensating health status.[2]
What these studies may mean for patients
These trials are not testing Sacubitril Valsartan in isolation, but as part of broader heart failure care.[1][2] They may help researchers understand whether treatment is being used fairly, whether treatment changes improve outcomes, and whether blood testing can help guide therapy better.[1][2]
Because the studies focus on heart failure, the findings are most relevant for people living with this condition, especially women and patients with reduced ejection fraction.[1][2]
